ADMA Biologics to Report Third Quarter 2026 Financial Results on November 4, 2026
Key Highlights
- ➤ADMA will report third quarter 2026 financial results November 4, 2026
- ➤Results will be released after U.S. financial markets close
- ➤Management will host a conference call and webcast at 4:30 p.m. ET
- ➤ADMA manufactures and markets three FDA-approved plasma-derived biologics
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 28, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S.-based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced that it will report third quarter 2026 financial results on November 4, 2026, after the U.S. financial markets close. ADMA’s management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other Company updates.
To access the conference call seamlessly, participants are required to register for the call here to receive the dial-in numbers and unique PIN. It is recommended that you join approximately 10 minutes prior to the event start (although you may dial in at any time during the call). Attendees who will not be asking a question during the call are encouraged to listen in to the live webcast here. An archived replay of the event will be available located under “Events & Webcasts” in the investor section of the Company’s website at https://ir.admabiologics.com/events-webcasts.
Get started
Create a free account to read the full story.
